R & D

Immune cell therapy : Stomach cancer

Cause

The immune cell therapy can selectively treat the target tumor cells, and prevent the recurrence and metastasis of the tumor by inducing the memory function of the human immune system during treatment. In addition, the use of customized autologous cells eliminates immune rejection, and this therapy can be applied to all solid tumors, and is applicable to infectious diseases.

Product

This technology is a procedure to prompt immune enhancement by selectively inducing the proliferation of specific lymphocyte NK, NKT, and T cells after isolation of lymphocytes from peripheral blood, and applying the activated lymphocytes to solid cancers such as gastric and colon cancer.

Results

Examination materials
Comparison of Peripheral Blood Mononuclear Cells (PBMC) and Activated Lymphocytes (TKCell)

Type CD3-LAK CIK NIKM CINK
Major
effector cell
Activated and expanded
Tlymphocytes (CD3+)
CD3(+) CD56(+) CD3(-) CD56(+)
CD3(+) CD56(+)
CD3(-) CD56(+)
CD3(+) CD56(+)
Company Innomedisys Greencrosscel (Inocell) Celltech (NKBio) Binex
Technology Origin Medinet (Japan) Lymphotec (Japan) Gojinbio Oda research (Japan) Independent development
Culture
Condition
PBMC Lymphocyte
OKT-3 and IL-2 IFN-g, OKT-3, IL2 and
IL-1b
OKT-3, IL-2 anti-CD16 and
anti-CD56
IFN-g, OKT-3 and
IL-2
14 days 2-4 weeks 14 days 21 days
Characteristics Advantages: It activates T-cells via the CD3 antibody and proliferates cells capable of killing virally infected and cancer cells. It is easy to grow and cultivate. Advantages: It is possible to selectively increase the number of lymphocytes (cdCD3-CD56+ cells) capable of killing cancer cells. The proliferation factor is greater than 1000x. Advantages: It is possible to selectively increase the number of lymphocytes (especially NK cells) capable of killing cancer cells. The proliferation factor is greater than 1000x. Advantages: It is possible to selectively increase the number of lymphocytes (especially NK cells) capable of killing cancer cells. The proliferation factor is greater than 1000x.
Disadvantages: Proliferation of T-cells is easy, but it is difficult to proliferate T cells with strong killing power. Disadvantages: it is difficult to induce ADCC because there are no CD16 + cells. Disadvantages: Clinically, an unsafe antibody is used to selectively increase the number of lymphocytes (especially NK cells) capable of killing cancer cells. Disadvantages: It takes longer to proliferate lymphocytes compared to T-cells which are easy to cultivate.
Proliferation of weak killing power T-cells Proliferation is high but ADCC can not be induced High killing power and proliferation High killing power and proliferation
High expression level of NKG2D
Regulatory T cell level It does not take into consideration regulatory T-cells that inhibit the immune function of the human body. Maintains normal levels (1-5%)

CD3-LAK

Major effector cell :

Activated and expanded Tlymphocytes (CD3+)

Company :

이노메디시스

원천기술 :

메디넷 (일본)

Culture Condition :

– PBMC
– OKT-3 and IL-2
– 14 days

특징 :

장점 : CD3항체에 의해 T세포를 활성화 시켜 바이러스 감염 세포나 암세포를 살상하는 능력을 가지는 세포를 증식시킨 것으로 증식이 쉽고 배양이 간단함
단점 : T세포의 증식은 쉽지만 살상력이 강한 T세포를 증식 시키는 것은 어려움.
– 살상력이 약한 T세포의 증식

Regulatory T cell level :

인체의 면역 기능을 억제시키는 Regulatory T cell에 대해 고려하지 않고 있음

CIK

Major effector cell :

CD3(+) CD56(+)

Company :

녹십자셀 (이노셀)

원천기술 :

림포텍 (일본)

Culture Condition :

– PBMC
– IFN-g, OKT-3, IL2 and IL-1b
– 2-4 weeks

특징 :

장점 : 암세포를 살상하는 능력이 있는 림프구 (cdCD3-CD56+ 세포)를 선택적 으로 늘리는 것이 가능 증식 기능 배율은 1000배이상
단점 : CD16+인 세포가 없기 때문에 ADCC를 유도하기 어려움.
– 증식력은 높으나 ADCC를 유도할 수 없음

Regulatory T cell level :

인체의 면역 기능을 억제시키는 Regulatory T cell에 대해 고려하지 않고 있음

NIKM

Major effector cell :

CD3(-) CD56(+), CD3(+) CD56(+)

Company :

셀텍 (NK바이오)

원천기술 :

고진바이오 오다연구소(일본)

Culture Condition :

– PBMC
– OKT-3, IL-2 anti-CD16 and anti-CD56
– 14 days

특징 :

장점: 암세포를 살상하는 능력이 강한 림프구(특히 NK 세포)를 선택적으로 늘리는 것이 가능 증식 기능 배율은 1000배 이상
단점: 암세포를 살상하는 능력이 강한 림프구(특히 NK 세포)를 선택적으로 늘리기 위해 임상적으로 안전성이 확보되지 않은 항체를 원료로 사용.
– 살상력과 증식력이 높음

Regulatory T cell level :

인체의 면역 기능을 억제시키는 Regulatory T cell에 대해 고려하지 않고 있음

CD3-LAK

Major effector cell :

CD3(-) CD56(+), CD3(+) CD56(+)

Company :

바이넥스

원천기술 :

독자개발

Culture Condition :

– Lymphocyte
– IFN-g, OKT-3 and IL-2
– 21 days

특징 :

장점: 암세포를 살상하는 능력이 강한 림프구(특히 NKK 세포)를 늘리는 것이 가능 증식 기능 배율은 1000배 이상
단점: T세포 등의 배양이 용이한 림프구에 비하면 증식 시키는데 시간이 오래걸림.
– 살상력과 증식력이 높음, NKG2D 발현량 높음

Regulatory T cell level :

정상수준으로 유지(1-5%)

Clinical study

In gastric and colorectal cancer clinical trials, complete or partial disappearance of metastatic lesions are shown before and after administration